Ramucirumab for the treatment of gastroesophageal cancers. - Wikidata - wikimedia - TriplyDB

Ramucirumab for the treatment of gastroesophageal cancers.

Ramucirumab for the treatment of gastroesophageal cancers.

http://www.wikidata.org/entity/Q37211153

about

Ramucirumab for the treatment of gastroesophageal cancers.

http://www.wikidata.org/entity/Q37211153

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 May 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Ramucirumab for the treatment of gastroesophageal cancers.

@en

Ramucirumab for the treatment of gastroesophageal cancers.

@nl

type

label

Ramucirumab for the treatment of gastroesophageal cancers.

@en

Ramucirumab for the treatment of gastroesophageal cancers.

@nl

prefLabel

Ramucirumab for the treatment of gastroesophageal cancers.

@en

Ramucirumab for the treatment of gastroesophageal cancers.

@nl

P1433

Q37211153-D130ED4B-EEA0-4011-BFF7-37DEB61B6107

P1476

Q37211153-19B4CB97-9C43-4C9A-80BA-798041299792

P2093

Q37211153-20A6A994-DE80-4DC4-A0E1-A4001F781AB6

Q37211153-4A532D4E-1590-4CD3-AE2E-58AE42A4BA45

Q37211153-6452E63B-C8CF-419B-BEEC-53B546E9BE3C

Q37211153-649BFD83-7F2C-443D-A3B7-7699D592AF25

Q37211153-BFD1DB21-3099-43F7-A235-96FF27E02EE5

Q37211153-C545BD61-3108-4121-89D3-D402CA1D8110

Q37211153-D5F1ED67-E414-4881-B555-9459F5E93D98

P2860

Q37211153-01F7EC66-0A4B-4221-ABEA-674F081023E1

Q37211153-02F8E421-104B-48F1-BFDD-4BA102C3F478

Q37211153-036E22B0-AD0C-4A5B-815E-FB0DAB23560F

Q37211153-0919CBB3-1D20-42F3-A4D0-CFAA50FB99B1

Q37211153-1209A8B5-745B-41BA-8FCB-FCD5C9C98F16

Q37211153-121A8C7D-9D11-4421-A35A-B8F5A6E2E157

Q37211153-12EF0461-A23B-48BD-8C23-B157B3755256

Q37211153-17F03550-B47F-4972-9225-CF7907A65161

Q37211153-1E2D6876-67E3-4E44-BA04-9797D9AFD9B1

Q37211153-1E9CE8F7-0A45-4FC7-B6D6-A94F10B4FCC2

P304

Q37211153-79D7C91F-9A9A-4ABE-A72E-564C36748CD5

P31

Q37211153-1968B5FB-473B-4331-9201-7792F2201806

P356

Q37211153-E0389D41-0DF5-491A-986B-240BF2A4DC2C

P433

Q37211153-448CC828-A25B-477B-A5FB-6B448B48565F

P478

Q37211153-CEC23D88-392F-4A7C-B4C1-C7EA4484C937

P50

Q37211153-8ECAA618-B68A-41EB-AF90-46DCCDB27D4E

Q37211153-BC69F6D1-47BC-4995-AC22-52785DB88C4D

P577

Q37211153-EEC4F9FB-53E9-409E-BDFC-574095F4BD01

P698

Q37211153-3E8383E6-0C3F-4B2C-86A0-D88BA04723C3

P932

Q37211153-248C1AB7-C0CD-4899-BB2E-8931080F4990

P356

21678707.2015.1040390

P1433

Expert opinion on orphan drugs

P1476

Ramucirumab for the treatment of gastroesophageal cancers.

@en

P2093

E Elimova

http://www.w3.org/2001/XMLSchema#string

H Shiozaki

http://www.w3.org/2001/XMLSchema#string

J E Rogers

http://www.w3.org/2001/XMLSchema#string

R Wadhwa

http://www.w3.org/2001/XMLSchema#string

S Song

http://www.w3.org/2001/XMLSchema#string

V Planjery

http://www.w3.org/2001/XMLSchema#string

Y Shimodaira

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Modes of resistance to anti-angiogenic therapy

Combining antiangiogenics to overcome resistance: rationale and clinical experience

Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies

The structural basis for the function of two anti-VEGF receptor 2 antibodies

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

P304

737-746

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/21678707.2015.1040390

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Nikolaos Charalampakis

P577

2015-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27570714

http://www.w3.org/2001/XMLSchema#string

P932

5001688

http://www.w3.org/2001/XMLSchema#string